TradeFlare's AI research teams analysed ERAS on 9 market nights between April 21, 2026 and September 18, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| September 18, 2026 | HOLD | $15.34 | — / — | -3.5% | not yet | The current setup does not warrant a buy recommendation due to conflicting signals and high risk. |
| August 14, 2026 | BUY | $17.86 | — / — | -4.1% | -12.1% | The current market regime and the stock's fundamental and risk profiles do not support a buy recommendation. |
| August 4, 2026 | HOLD | $17.84 | — / — | -0.4% | -8.8% | Positive clinical trial data for drug candidates. |
| July 30, 2026 | BUY | $17.72 | — / — | -2.2% | +4.3% | Positive clinical trial data for ERAS-0015. |
| July 29, 2026 | HOLD | $18.16 | — / — | +5.1% | +8.1% | Positive clinical trial data for ERAS-0015 could drive sentiment and price. |
| July 8, 2026 | HOLD | $18.36 | — / — | +12.7% | -1.3% | Post-earnings drift signal observed in the scanner. |
| May 4, 2026 | BUY | $10.03 | $12.86 / $8.53 | +3.0% | +32.9% | The current market regime is neutral, and the stock exhibits strong bearish technical, fundamental, and sentiment indicators, making a buy decision unwarranted. |
| April 22, 2026 | BUY | $22.41 | — / — | -57.9% | -48.6% | Successful clinical trial results for pipeline drugs. |
| April 21, 2026 | HOLD | $21.71 | — / — | -55.8% | -54.0% |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.